pemetrexed,carboplatin,pembrolizumab,medi-5752
astrazeneca,merck
['pemetrexed', 'kidney cancer', 'carboplatin', 'nsclc', 'medi5752 ', 'medi5752', 'sclc', 'pembro']
after promising activity in kidney cancer, the bispecific ab (pd-1/ctla-4) medi5752 combined with pemetrexed/carboplatin had favorable outcome vs. pem/carbo-pembrolizumab in patients with nsclc, enriched in pd-l1 neg. but very small cohorts! safety profile to be followed. #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.